Index RUT P/E - EPS (ttm) -1.97 Insider Own 27.00% Shs Outstand 66.21M Perf Week 0.34%
Market Cap 198.78M Forward P/E - EPS next Y -1.25 Insider Trans 3.14% Shs Float 48.53M Perf Month -6.85%
Income -126.61M PEG - EPS next Q -0.40 Inst Own 67.01% Short Float 2.35% Perf Quarter 66.11%
Sales 5.90M P/S 33.69 EPS this Y 27.92% Inst Trans 0.85% Short Ratio 4.71 Perf Half Y 224.72%
Book/sh 3.07 P/B 0.97 EPS next Y 11.87% ROA -33.72% Short Interest 1.14M Perf Year -35.28%
Cash/sh 3.98 P/C 0.75 EPS next 5Y - ROE -52.14% 52W Range 0.86 - 6.98 Perf YTD 81.21%
Dividend Est. - P/FCF - EPS past 5Y -20.44% ROI -43.23% 52W High -57.16% Beta 2.82
Dividend TTM - Quick Ratio 6.83 Sales past 5Y -20.00% Gross Margin 10.86% 52W Low 247.67% ATR (14) 0.34
Dividend Ex-Date - Current Ratio 6.83 EPS Y/Y TTM 16.45% Oper. Margin -2227.95% RSI (14) 44.20 Volatility 10.47% 10.91%
Employees 174 Debt/Eq 0.48 Sales Y/Y TTM - Profit Margin -2144.51% Recom 1.86 Target Price 7.50
Option/Short Yes / Yes LT Debt/Eq 0.44 EPS Q/Q 2.36% Payout - Rel Volume 0.47 Prev Close 3.26
Sales Surprise 128.29% EPS Surprise -14.97% Sales Q/Q - Earnings Mar 06 AMC Avg Volume 242.41K Price 2.99
SMA20 -17.69% SMA50 -1.98% SMA200 0.90% Trades
Volume 114,490 Change -8.28%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-19-23 Downgrade TD Cowen
Outperform → Market Perform
Nov-08-22 Initiated Canaccord Genuity
Buy
$9
Dec-14-21 Downgrade William Blair
Outperform → Mkt Perform
Jun-08-21 Initiated JMP Securities
Mkt Outperform
$40
Feb-24-21 Initiated William Blair
Outperform
Feb-18-21 Initiated Needham
Buy
$50
Jul-07-20 Initiated Wedbush
Outperform
$31
Jul-07-20 Initiated JP Morgan
Overweight
$28
Jul-07-20 Initiated Jefferies
Buy
$38
Jul-07-20 Initiated Cowen
Outperform
Apr-22-24 05:31PM
Apr-02-24 06:59AM
Mar-08-24 04:32AM
Mar-06-24 10:52PM
05:40PM
04:20PM
Loading…
04:20PM
Feb-27-24 06:59AM
Jan-03-24 04:05PM
Dec-06-23 03:05AM
Nov-29-23 08:41AM
06:59AM
Nov-09-23 04:15PM
Oct-26-23 06:59AM
Oct-18-23 06:59AM
Sep-19-23 07:30AM
08:49AM
Loading…
Aug-03-23 08:49AM
07:30AM
Aug-02-23 07:05PM
04:15PM
May-31-23 07:30AM
May-10-23 06:05PM
04:15PM
May-09-23 04:15PM
Apr-11-23 07:30AM
Apr-10-23 09:40AM
Apr-05-23 07:30AM
Mar-24-23 03:02PM
Mar-23-23 10:43AM
07:29AM
07:00AM
04:15PM
Loading…
Mar-21-23 04:15PM
Feb-27-23 07:30AM
Feb-24-23 07:18AM
Feb-23-23 04:28PM
Jan-03-23 04:30PM
Dec-05-22 09:55AM
Nov-17-22 09:55AM
Nov-03-22 04:15PM
Nov-01-22 08:07AM
Sep-22-22 07:30AM
Sep-20-22 07:30AM
Sep-17-22 08:12AM
Aug-04-22 05:45PM
04:15PM
Aug-02-22 04:15PM
Jul-18-22 07:30AM
Jul-11-22 09:55AM
Jun-21-22 08:30AM
Jun-02-22 07:30AM
May-25-22 06:37AM
May-05-22 07:05PM
04:15PM
Apr-05-22 07:30AM
Mar-25-22 12:00PM
10:00AM
Mar-02-22 07:30AM
Feb-24-22 04:20PM
Feb-10-22 07:30AM
Jan-05-22 07:30AM
Dec-28-21 07:37PM
Dec-19-21 09:37PM
Dec-16-21 11:02PM
06:38PM
07:01AM
Dec-14-21 06:30AM
12:38AM
Nov-10-21 04:20PM
Oct-22-21 07:30AM
Oct-21-21 04:05PM
Oct-15-21 07:30AM
Sep-30-21 11:12AM
Sep-17-21 08:34AM
Aug-11-21 04:20PM
Aug-03-21 07:30AM
Jul-14-21 07:30AM
Jul-08-21 07:30AM
Jun-19-21 05:55AM
Jun-09-21 07:30AM
May-27-21 07:30AM
May-12-21 04:20PM
Apr-27-21 04:35PM
Apr-08-21 07:30AM
Mar-21-21 05:20AM
Mar-18-21 08:00AM
Mar-01-21 08:53AM
Feb-18-21 10:02AM
07:30AM
Jan-13-21 11:29PM
Jan-11-21 05:43PM
Jan-06-21 09:24PM
Jan-05-21 08:44AM
06:30AM
Jan-04-21 06:30AM
Dec-13-20 03:52AM
Dec-02-20 11:34PM
Nov-10-20 06:30AM
Oct-31-20 08:00AM
Oct-05-20 06:30AM
Sep-24-20 06:30AM
Sep-14-20 10:59AM
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Samayoa Phillip CHIEF STRATEGY OFFICER Jan 02 '24 Sale 1.62 2,445 3,961 107,256 Jan 03 04:35 PM Paone Antoinette CHIEF OPERATING OFFICER Jan 02 '24 Sale 1.62 2,445 3,961 5,828 Jan 03 04:35 PM Appelhans Dannielle Director Dec 08 '23 Buy 1.79 7,363 13,180 7,363 Dec 11 04:30 PM Appelhans Dannielle Director Dec 08 '23 Buy 1.82 637 1,159 12,637 Dec 11 04:30 PM Rowland Charles A Jr Director Dec 04 '23 Buy 1.50 150,000 225,000 534,757 Dec 05 04:30 PM Appelhans Dannielle Director Dec 04 '23 Buy 1.50 12,000 18,000 12,000 Dec 06 04:30 PM Rowland Charles A Jr Director Dec 01 '23 Buy 1.31 192,960 252,778 384,757 Dec 05 04:30 PM Nicholson Donald William Director Dec 01 '23 Buy 1.44 100,000 144,000 213,576 Dec 05 04:30 PM Quinn Anthony G. Director Dec 01 '23 Buy 1.41 88,495 124,778 88,495 Dec 05 04:30 PM Paone Antoinette CHIEF OPERATING OFFICER Aug 23 '23 Sale 4.93 3,116 15,362 2,914 Aug 25 04:35 PM Samayoa Phillip CHIEF STRATEGY OFFICER Jul 03 '23 Sale 5.29 3,116 16,484 101,428 Jul 05 04:35 PM
Index RUT P/E - EPS (ttm) -8.37 Insider Own 2.33% Shs Outstand 61.15M Perf Week 4.39%
Market Cap 5.65B Forward P/E - EPS next Y -2.81 Insider Trans -11.99% Shs Float 59.80M Perf Month 4.58%
Income -506.98M PEG - EPS next Q -1.67 Inst Own 106.32% Short Float 7.31% Perf Quarter 12.68%
Sales 249.38M P/S 22.65 EPS this Y 33.17% Inst Trans -2.82% Short Ratio 5.53 Perf Half Y 108.97%
Book/sh 2.14 P/B 43.19 EPS next Y 49.80% ROA -42.26% Short Interest 4.37M Perf Year 92.01%
Cash/sh 11.61 P/C 7.95 EPS next 5Y - ROE -157.13% 52W Range 43.89 - 101.00 Perf YTD 0.02%
Dividend Est. - P/FCF - EPS past 5Y -9.19% ROI -61.58% 52W High -8.65% Beta 0.65
Dividend TTM - Quick Ratio 3.66 Sales past 5Y 220.20% Gross Margin 87.46% 52W Low 110.21% ATR (14) 4.32
Dividend Ex-Date - Current Ratio 3.76 EPS Y/Y TTM 10.38% Oper. Margin -194.99% RSI (14) 54.99 Volatility 5.83% 4.54%
Employees 655 Debt/Eq 5.93 Sales Y/Y TTM 22.22% Profit Margin -203.30% Recom 1.94 Target Price 97.47
Option/Short Yes / Yes LT Debt/Eq 5.30 EPS Q/Q 31.25% Payout - Rel Volume 0.71 Prev Close 92.29
Sales Surprise 7.21% EPS Surprise 10.77% Sales Q/Q 85.55% Earnings May 02 BMO Avg Volume 790.23K Price 92.26
SMA20 1.73% SMA50 2.88% SMA200 32.07% Trades
Volume 561,326 Change -0.03%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-27-23 Upgrade Oppenheimer
Perform → Outperform
$85
Aug-21-23 Reiterated Needham
Buy
$65 → $66
Jul-31-23 Upgrade Wells Fargo
Equal Weight → Overweight
$55 → $82
Jun-05-23 Downgrade SVB Securities
Market Perform → Underperform
$48 → $43
Jan-03-23 Upgrade Wells Fargo
Underweight → Equal Weight
$41
Dec-14-22 Initiated Needham
Buy
$60
Nov-02-22 Downgrade Oppenheimer
Outperform → Perform
Sep-14-22 Initiated Berenberg
Buy
$90
Jul-08-22 Initiated Oppenheimer
Outperform
$80
Jun-27-22 Initiated Wells Fargo
Underweight
$40
Jun-10-22 Downgrade Citigroup
Neutral → Sell
$68 → $41
Jun-01-22 Upgrade Jefferies
Hold → Buy
$88 → $78
Mar-01-22 Initiated Citigroup
Neutral
$71
Feb-17-22 Downgrade SVB Leerink
Outperform → Mkt Perform
$82
Jan-25-22 Upgrade Stifel
Hold → Buy
$120 → $95
Nov-19-21 Resumed Morgan Stanley
Equal-Weight
$111
Sep-30-21 Resumed Stifel
Hold
$105
Jun-04-21 Resumed Robert W. Baird
Outperform
$119
Mar-31-21 Initiated Credit Suisse
Neutral
$100
Dec-03-20 Initiated Stifel
Hold
$110
Show Previous Ratings
Apr-18-24 08:00AM
Apr-11-24 08:00AM
Apr-04-24 04:01PM
Mar-28-24 08:13AM
Mar-17-24 08:50AM
07:00PM
Loading…
Mar-15-24 07:00PM
Mar-06-24 04:01PM
11:53AM
(Thomson Reuters StreetEvents)
Feb-23-24 08:00AM
Feb-16-24 03:30PM
09:37AM
05:47AM
Feb-15-24 10:50PM
(Thomson Reuters StreetEvents) +14.02%
10:55AM
(Investor's Business Daily)
08:25AM
07:43AM
Loading…
07:43AM
07:26AM
(Associated Press Finance)
07:00AM
(Investor's Business Daily)
07:00AM
Feb-12-24 09:16AM
Feb-08-24 10:00AM
Feb-05-24 04:01PM
Feb-01-24 08:00AM
Jan-16-24 12:00PM
11:51AM
Jan-09-24 01:51PM
Jan-08-24 08:00AM
Jan-05-24 04:01PM
Dec-18-23 08:00AM
Dec-14-23 11:05AM
08:05AM
Loading…
Dec-12-23 08:05AM
Dec-10-23 11:59AM
Dec-09-23 12:30PM
Dec-04-23 04:01PM
Nov-28-23 08:00AM
Nov-14-23 05:05PM
Nov-13-23 04:29PM
Nov-10-23 08:00AM
Nov-04-23 03:02AM
Nov-03-23 04:01PM
Oct-31-23 09:55AM
09:40AM
03:48AM
Oct-30-23 03:46PM
Oct-28-23 01:49PM
Oct-27-23 10:01AM
07:27AM
Oct-26-23 11:42PM
(Thomson Reuters StreetEvents) +25.61%
05:47PM
09:30AM
08:52AM
08:15AM
07:09AM
(Associated Press Finance)
07:00AM
Oct-25-23 10:15AM
Oct-23-23 08:30AM
Oct-20-23 10:00AM
Oct-19-23 10:01AM
Oct-12-23 08:00AM
Oct-06-23 03:00AM
Oct-05-23 04:01PM
Sep-29-23 11:01PM
Sep-08-23 11:30AM
Sep-07-23 11:30AM
Sep-05-23 04:01PM
Sep-01-23 11:31AM
Aug-04-23 04:16PM
Aug-02-23 01:00PM
12:42PM
09:30AM
08:25AM
07:14AM
07:00AM
Jul-19-23 08:00AM
Jul-14-23 11:53AM
Jul-05-23 04:30PM
Jun-30-23 08:56AM
06:26AM
Jun-12-23 09:30AM
Jun-09-23 09:22AM
Jun-05-23 05:00PM
Jun-04-23 08:45AM
Jun-03-23 09:00AM
May-23-23 10:00AM
May-22-23 04:04PM
May-05-23 06:54AM
May-04-23 05:01PM
08:25AM
07:25AM
07:00AM
May-01-23 10:01AM
Apr-27-23 10:02AM
Apr-26-23 10:00AM
Apr-20-23 04:01PM
Apr-19-23 08:07AM
Apr-11-23 08:00AM
Apr-05-23 04:01PM
Mar-31-23 11:30AM
Mar-29-23 08:31AM
Mar-28-23 04:05PM
Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Landsittel Michael CHIEF FINANCIAL OFFICER Mar 28 '24 Option Exercise 36.05 5,000 180,250 52,286 Apr 01 04:34 PM Landsittel Michael CHIEF FINANCIAL OFFICER Mar 28 '24 Sale 95.00 5,000 475,000 47,286 Apr 01 04:34 PM Albers Jeffrey W. Director Mar 20 '24 Option Exercise 7.11 25,073 178,287 201,123 Mar 22 05:50 PM Albers Jeffrey W. Director Mar 20 '24 Sale 87.28 25,073 2,188,264 176,050 Mar 22 05:50 PM Landsittel Michael CHIEF FINANCIAL OFFICER Mar 15 '24 Option Exercise 36.05 5,000 180,250 61,020 Mar 19 05:11 PM Hurley Ariel PRINCIPAL ACCOUNTING OFFICER Mar 15 '24 Option Exercise 15.01 1,600 24,016 18,662 Mar 19 04:48 PM Landsittel Michael CHIEF FINANCIAL OFFICER Mar 15 '24 Sale 87.78 13,734 1,205,606 47,286 Mar 19 05:11 PM Hurley Ariel PRINCIPAL ACCOUNTING OFFICER Mar 15 '24 Sale 87.76 4,549 399,213 14,913 Mar 19 04:48 PM Lee Philina CHIEF COMMERCIAL OFFICER Mar 13 '24 Option Exercise 13.15 1,747 22,975 42,752 Mar 15 04:47 PM Lee Philina CHIEF COMMERCIAL OFFICER Mar 13 '24 Sale 90.40 8,023 725,277 34,729 Mar 15 04:47 PM Haviland Kate CHIEF EXECUTIVE OFFICER Mar 07 '24 Sale 90.69 12,464 1,130,360 153,177 Mar 11 06:27 PM Albers Jeffrey W. Director Mar 07 '24 Sale 90.69 11,033 1,000,583 165,017 Mar 26 09:11 PM Rossi Christina CHIEF OPERATING OFFICER Mar 07 '24 Sale 90.69 6,070 550,488 64,306 Mar 11 06:21 PM McCain Tracey L EVP AND CHIEF LEGAL OFFICER Mar 07 '24 Sale 90.69 5,194 471,044 60,498 Mar 11 06:18 PM Durso-Bumpus Debra CHIEF PEOPLE OFFICER Mar 07 '24 Sale 90.69 5,093 461,884 57,585 Mar 11 06:28 PM Landsittel Michael CHIEF FINANCIAL OFFICER Mar 07 '24 Sale 90.69 5,003 453,722 56,020 Mar 11 06:23 PM Namouni Fouad PRESIDENT, R & D Mar 07 '24 Sale 90.69 4,377 396,950 72,703 Mar 11 06:20 PM Hewes L. Becker CHIEF MEDICAL OFFICER Mar 07 '24 Sale 90.69 3,097 280,867 46,281 Mar 11 06:29 PM Lee Philina CHIEF COMMERCIAL OFFICER Mar 07 '24 Sale 90.69 2,934 266,084 41,005 Mar 11 06:26 PM Murray Christopher K. CHIEF TECHNICAL OPERATIONS Mar 07 '24 Sale 90.69 2,521 228,629 33,853 Mar 11 06:24 PM Carter Percy H. CHIEF SCIENTIFIC OFFICER Mar 07 '24 Sale 90.69 2,286 207,317 48,331 Mar 11 06:19 PM Hurley Ariel PRINCIPAL ACCOUNTING OFFICER Mar 07 '24 Sale 90.69 1,462 132,589 17,862 Mar 11 06:15 PM Murray Christopher K. CHIEF TECHNICAL OPERATIONS Mar 04 '24 Sale 93.65 621 58,157 36,374 Mar 06 10:41 AM Murray Christopher K. CHIEF TECHNICAL OPERATIONS Feb 28 '24 Option Exercise 54.13 5,000 270,650 29,495 Mar 01 03:06 PM Murray Christopher K. CHIEF TECHNICAL OPERATIONS Feb 28 '24 Sale 100.00 5,000 500,000 24,495 Mar 01 03:06 PM Albers Jeffrey W. Director Jan 25 '24 Option Exercise 7.13 25,000 178,150 201,050 Jan 29 06:13 PM Albers Jeffrey W. Director Jan 25 '24 Sale 81.91 25,000 2,047,800 176,050 Jan 29 06:13 PM Hurley Ariel PRINCIPAL ACCOUNTING OFFICER Dec 22 '23 Option Exercise 8.80 714 6,283 15,038 Dec 26 04:24 PM Hurley Ariel PRINCIPAL ACCOUNTING OFFICER Dec 22 '23 Sale 90.00 714 64,260 14,324 Dec 26 04:24 PM Hurley Ariel PRINCIPAL ACCOUNTING OFFICER Dec 15 '23 Option Exercise 1.87 3,654 6,833 16,411 Dec 19 04:05 PM Hurley Ariel PRINCIPAL ACCOUNTING OFFICER Dec 15 '23 Sale 84.35 3,914 330,146 14,324 Dec 19 04:05 PM Lee Philina CHIEF COMMERCIAL OFFICER Dec 13 '23 Option Exercise 1.87 261 488 31,439 Feb 14 06:54 PM Albers Jeffrey W. Director Dec 11 '23 Option Exercise 36.05 5,000 180,250 181,050 Dec 13 03:56 PM Albers Jeffrey W. Director Dec 11 '23 Sale 79.07 5,000 395,350 176,050 Dec 13 03:56 PM Murray Christopher K. CHIEF TECHNICAL OPERATIONS Dec 07 '23 Option Exercise 54.13 5,000 270,650 29,495 Dec 11 05:11 PM Murray Christopher K. CHIEF TECHNICAL OPERATIONS Dec 07 '23 Sale 75.00 5,000 375,000 24,495 Dec 11 05:11 PM Murray Christopher K. CHIEF TECHNICAL OPERATIONS Dec 04 '23 Sale 71.43 600 42,858 24,495 Dec 06 08:45 PM Albers Jeffrey W. Director Nov 30 '23 Option Exercise 36.05 5,000 180,250 181,050 Dec 04 04:02 PM Albers Jeffrey W. Director Nov 30 '23 Sale 70.55 5,000 352,750 176,050 Dec 04 04:02 PM Albers Jeffrey W. Director Nov 24 '23 Option Exercise 1.87 15,000 28,050 191,050 Nov 28 04:05 PM Albers Jeffrey W. Director Nov 24 '23 Sale 67.51 15,000 1,012,690 176,050 Nov 28 04:05 PM Albers Jeffrey W. Director Nov 03 '23 Option Exercise 36.05 1,485 53,534 177,535 Nov 03 05:07 PM Albers Jeffrey W. Director Nov 03 '23 Sale 60.13 1,485 89,293 176,050 Nov 03 05:07 PM Albers Jeffrey W. Director Nov 02 '23 Option Exercise 36.05 4,634 167,056 180,684 Nov 03 05:07 PM Albers Jeffrey W. Director Nov 02 '23 Sale 60.37 4,634 279,749 176,050 Nov 03 05:07 PM Albers Jeffrey W. Director Nov 01 '23 Option Exercise 36.05 3,881 139,910 179,931 Nov 03 05:07 PM Albers Jeffrey W. Director Nov 01 '23 Sale 60.02 3,881 232,938 176,050 Nov 03 05:07 PM Murray Christopher K. CHIEF TECHNICAL OPERATIONS Oct 26 '23 Sale 56.40 600 33,840 25,095 Oct 30 02:01 PM Namouni Fouad PRESIDENT, R & D Oct 04 '23 Sale 48.06 3,769 181,138 62,080 Oct 05 10:47 AM Albers Jeffrey W. Director Sep 28 '23 Option Exercise 1.87 6,898 12,899 182,948 Sep 29 02:36 PM Albers Jeffrey W. Director Sep 28 '23 Sale 50.17 6,898 346,073 176,050 Sep 29 02:36 PM Albers Jeffrey W. Director Sep 27 '23 Option Exercise 1.87 18,102 33,851 194,152 Sep 29 02:36 PM Albers Jeffrey W. Director Sep 27 '23 Sale 49.61 18,102 897,957 176,050 Sep 29 02:36 PM Albers Jeffrey W. Director Aug 25 '23 Option Exercise 1.87 10,000 18,700 186,050 Aug 28 06:23 PM Albers Jeffrey W. Director Aug 25 '23 Sale 50.16 10,000 501,600 176,050 Aug 28 06:23 PM Albers Jeffrey W. Director Aug 24 '23 Option Exercise 1.87 15,000 28,050 191,050 Aug 28 06:23 PM Albers Jeffrey W. Director Aug 24 '23 Sale 49.57 15,000 743,550 176,050 Aug 28 06:23 PM Carter Percy H. CHIEF SCIENTIFIC OFFICER Jun 05 '23 Sale 52.06 2,307 120,102 38,117 Jun 07 07:52 PM Hewes L. Becker CHIEF MEDICAL OFFICER Jun 05 '23 Sale 52.05 1,404 73,078 36,878 Jun 07 07:48 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
